550 likes | 781 Views
The role of immune responses in HIV-1 Infection. Marylyn M. Addo, MD/PhD Partners AIDS Research Center Massachusetts General Hospital Harvard Medical School Boston, MA USA. Natural History of HIV-1. symptoms. 1000. 10 6. CD4. 800. 10 5. HIV RNA copies/ml. HIV RNA. 600. VZV TB
E N D
The role of immune responses in HIV-1 Infection Marylyn M. Addo, MD/PhD Partners AIDS Research Center Massachusetts General Hospital Harvard Medical School Boston, MA USA
Natural History of HIV-1 symptoms 1000 106 CD4 800 105 HIV RNA copies/ml HIV RNA 600 VZV TB Kaposi Sarcoma CD4 per mm3 104 400 200 PCP CMV MAC Crypto Lymphoma 1 5 10 15 • Time (years)
One year The level of HIV in the blood stream predicts subsequent survival Rapid Progression RNA particles/ml plasma Viral set point Slow Progression
New virus assembly 2-3 Days
Viral set point is determined by number of viruses produced by infected cells
Potential factors influencing the viral set point Attenuated virus Host immune response Host genetic factors
Potential factors influencing the viral set point Attenuated virus Host immune response Host genetic factors HAART
New virus assembly 2-3 Days Example: Sidney blood bank cohort Virus had a “mistake” in the nef gene Attenuated viruses
Host genetic factors Attenuated viruses
Co-receptor polymorphisms can prevent entry of virus into cells 32 base pair deletion in CCR5 CD4 CCR5
Some molecules on the cell of an individual are associated with improved viral control and slow disease progression B27 B57 Migueles, PNAS 97:2709, 2000
Host genetic factors Attenuated viruses Host immune responses
B cell New virus assembly Humoral Immune System: Neutralizing Antibodies
Soluble factors CTL New virus assembly Cellular immune system: Killer T cells Cytotoxic T cell
CTL B cell New virus assembly Th Th Soluble factors
Th B cell CTL Th
The Generals (T helper cells trained to target HIV)
Enemy Infected cell Infantry (CTL) Generals (T Helper cells)
Enemy Infected cell Infantry (CTL) Generals (T Helper cells)
Virus-Specific T Helper Cells:Essential for Maintenance of Effective CTL Viremia CTL Relative magnitude Viremia CTL Th cells present Th cells absent
Is there any way to enhance the immune response against HIV?
Enemy (Infected cells) Infantry (CTL) Generals (T helper cells)
HAART Enemy (Infected cell) Infantry (CTL) Generals (T Helper cells)
Effect of Early Treatment on the Generals (HIV-Specific T Helper Cells) 1000 100 Magnitude of Helper Cells 10 1 0 20 40 60 80 Weeks on Treatment
HAART Early treatment of acute HIV infection followed by treatment interruption 160000 120000 viral load (copies RNA/mL) 80000 40000 0 0 5 10 15 20 25 30 35 40 Weeks after first treatment interruption
Very early treatment with HAART leads to enhanced natural control of HIV
Where else do we find evidence for immune control in AIDS virus infection ? • In monkey studies, removing killer cells led to dramatic increases in viral load and restoring Killer T cells in those same monkey studies led to suppression of viral load • Individuals with high levels of Killer T cells have been shown to have low viral loads • Two interesting groups of individuals • HIV-1 long-term nonprogressors (LTNP) • HIV-1 exposed, but uninfected individuals (HEPS)
LTNP • Infected 21 years • Normal T cells • Undetectable viral load • Never on anti-HIV meds LTNP have strong and broadly directed killer cell responses and helper cell responses
HEPS • Most well known: • Nairobi sex worker cohort (Rowland-Jones et al.) • Found killer T cell responses in these HEPS, that may contribute to protection from HIV • Our group: collaboration with Lusaka, Zambia (PI: Susan Allen) studying killer cells in discordant couples and their partners Poster session Thursday 12-2 pm (Addo)
Based on these pieces of data, it is felt that an effective HIV-1 vaccine needs to elicit cellular immune responses, in particular Killer T cell responses +/- Helper T cell responses Most recent and compelling data derive from monkey studies demonstrating that Killer T cell have an impact on vaccine efficacy in this setting (Robbinson, Barouch/Letvin, Shiver) Many vaccine approaches/trials currently in study Vaccine development
Our current Research • Understanding of total the killer T cell and helper cell response against HIV, not only to single proteins like previous studies. • Analysis of the virus by sequencing Bruce Walker morning Tuesday plenary Addo A05 Tuesday 14-15:30
More research needed for other virus types and other ethnicities • Durban, RSA • Immune responses in Clade C-Infection • Mother to child transmission and pediatric treatment and treatment interruption studies • NIH contract Epitope mapping in Non-Caucasians
Lab Nelson Mandela School of Medicine University of Natal
Why is HIV not controlled by the immune system like other chronic viral infections? Mono Chicken pox Herpes simplex
Problems • VIRAL ESCAPE • VIRAL DIVERSITY
Viral escape Examples: • Goulder et al, Nature 2001 • Viral escape mutants can be transmitted from mother to child • Barouch et al, Nature 2002 • Loss of viral control in a vaccinated animal associated with viral escape in one epitope
Viral DiversityComparing Viruses:How much does HIV evolve compared to Flu? More Variation Less Variation
1997-1998 Canadian Flu 1996 Global Flu Influenza variation compared to HIV variation
1997-1998 Canadian Flu 1996 Global Flu Influenza variation compared to HIV variation 1990-1991 Amsterdam 1997 Dem Rep of Congo
The extreme variability of HIV over time is a major impediment to immune control, effective drug therapy and vaccine development
Acknowledgements • Marcus Altfeld • Xu Yu • Almas Rathod • Cecily Fitzpatrick • Paul Lee • Philip Goulder • Christian Brander • Eric Rosenberg • Bruce Walker Funding Sources: German Research Council (DFG) amfAR Concerned Parents for AIDS Research (CPFA)
HLA-B27 is associated with slow progression to AIDS 106 105 Viral Load 104 n = 10 HLA-B27+ 103 102
The dominant CTL response in HLA-B27+ individuals: HIV Gag p24 KK10 epitope K I L G L W I L R K HLA B27 molecule